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Antithyroid drugs and birth defects
Stine Linding Andersen1,2,3* and Stig Andersen2,4
Abstract
Antithyroid drugs (ATDs) are preferred for the treatment of hyperthyroidism caused by Graves’ disease in pregnant
women. The drugs have been a recognized treatment for decades, and a general risk of side effects is known. For
the use of ATDs in pregnancy, a concern about teratogenic side effects has been brought forward since the 1970s.
In more recent years, a number of large observational studies have added new evidence and quantified the risk of
birth defects associated with different types of ATDs. The findings that both Methimazole (MMI) and
Propylthiouracil (PTU) are associated with birth defects have challenged the clinical recommendations on the
treatment of hyperthyroidism in pregnancy, and certain aspects remain unclarified. In this review, the current
evidence on the risk of birth defects associated with the use of ATDs in early pregnancy is described, and
determinants of causality are discussed. This includes the current evidence of a biological gradient and the role of
maternal thyroid function per se. Finally, clinical aspects of the timing and type of treatment is discussed, and
future perspectives are addressed. Current evidence corroborates a risk of birth defects associated with MMI while
more evidence is needed to determine the teratogenic potential of PTU. Detailed assessment of type and timing of
exposure in large cohorts are needed. Moreover, studies investigating alternative or new treatments are warranted.
Keywords: Pregnancy, Hyperthyroidism, Graves’ disease, Birth defects, Congenital malformations, Antithyroid drugs,
Methimazole, Carbimazole, Propylthiouracil
Introduction
Antithyroid drugs (ATDs) have been used in clinical
practice for the treatment of hyperthyroidism for more
than half a century and constitute a recognized treat-
ment in non-pregnant and in pregnant individuals [1].
In pregnancy, the hyperthyroidism of Graves’ disease
(GD) should be treated to prevent maternal and fetal
complications, and ATDs are the treatment of choice
[2–4]. Radioiodine should not be used in pregnancy, and
surgery is preferably avoided [2–4]. A long known and
general concern about the use of ATDs is the risk of side
effects [5]. The most common side effects are less severe
and typically cutaneous reactions [5]. On other hand, se-
vere side effects related to treatment with ATDs such as
agranulocytosis and liver failure are rare [5]. For the use
of ATDs in pregnancy, adverse side effects may affect
not only the pregnant woman, but also the developing
fetus [6]. Increasing evidence has pointed towards a risk
of birth defects associated with the use of ATDs for the
treatment of hyperthyroidism in pregnant women, and the
findings that a teratogenic risk may apply to all available
ATDs challenge the clinical recommendations [2–4].
In this review, the current state of the art on the risk
of birth defects associated with maternal use of ATDs in
pregnancy is described, and methodological aspects are
discussed. Furthermore, the review specifically addresses
the existing knowledge on determinants of causality in-
cluding the impact of the dose of ATDs and maternal
thyroid function per se. Finally, perspectives on the tim-
ing of exposure and alternative or new treatments in
pregnancy are introduced.
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ATDs and birth defects
ATDs are thionamides that block the synthesis of thy-
roid hormones [5]. The facts that the drugs are not nat-
urally occurring in humans and that they interrupt an
endogenous synthesis raise a concern about adverse ef-
fects. The available ATDs include Methimazole (MMI)
and its prodrug Carbimazole (CMZ) as well as Pro-
pylthiouracil (PTU) [1]. In non-pregnant individuals,
MMI is preferred for initial treatment due to the phar-
macokinetic profile and less severe side effects [2, 4].
The initial choice of treatment differs in pregnant
women, and PTU is recommended for the treatment of
hyperthyroidism in early pregnancy due to a risk of birth
defects associated with the use of MMI [2–4].
A possible link between the use of ATDs and birth de-
fects was first described 50 years ago. From the early re-
port in 1972 [7], case reports and case series encircled a
pattern of severe malformations after maternal use of
MMI in early pregnancy including aplasia cutis, choanal
atresia, esophageal atresia, omphalocele, and omphalome-
senteric duct anomalies [8]. These findings led to the pro-
posal of an MMI embryopathy in the 1990s [9].
Consequently, PTU was recommended for the treatment of
maternal hyperthyroidism in the beginning of the twenty-
first century, but uncertainties on the teratogenic profile of
MMI prevailed [10, 11]. Another decade went past before
the first observational studies that included non-exposed
control groups were published [12]. During the 2010s, a
number of observational studies have emerged that evalu-
ated the association between exposure to ATDs in early
pregnancy and birth defects (Figs. 1 and 2). The studies
cover different populations in Asia (Taiwan [17], Japan
[13], Korea [14]), Europe (Denmark [15, 16], Sweden [18],
Italy [19]), and the United States (US) [20, 21]. Some stud-
ies found an association (Fig. 1), while others did not
(Fig. 2). As previously discussed, a number of methodo-
logical differences between the studies may explain this
disparity [12]. Firstly, the studies from Japan, Denmark, and
Korea that detected an association included a large number
of exposed children (Fig. 1). All these studies included more
than 1000 MMI-exposed children and found that exposure
to MMI was associated with a higher risk of birth defects
(Fig. 1). An important similarity among the studies that ob-
served an association with MMI (Fig. 1) was a risk of the
severe malformations previously described as part of the
MMI embryopathy. In contrast, the studies that did not de-
tect an association with MMI included less than 200 ex-
posed children (Fig. 2), but it is to be noted that more than
half of the studies that found no association with either
MMI or PTU included more the 500 PTU-exposed chil-
dren. As discussed in further detail below, other determi-
nants besides the number of exposed children may be of
importance when evaluating and comparing study results.
This includes the selection and definition of the non-
exposed group, the method used for assessment of expos-
ure and outcome, the timing of exposure and the age of the
child at follow-up for the diagnosing of birth defects.
Considering PTU, this drug had not been linked to
birth defects by the turn of the century [11] and the ma-
jority of later observational studies found no association
between maternal use of PTU in early pregnancy and
birth defects including the large study from Japan pub-
lished in 2012 (Figs. 1 and 2). On the other hand, the
subsequent studies from Denmark in 2013 and Korea in
2018 eported that PTU was associated with a higher
frequency of birth defects as opposed to non-exposed
(Fig. 1). The finding that PTU was associated with birth
defects was new and challenged the clinical guidelines
on which drug to use and further studies were warranted
to corroborate the findings. A follow-up to the Danish
study was published in 2019 that extended the cohort to
recent years and included children born from 1997 to
2016. In this extended cohort, an association between
the use of ATDs in early pregnancy and birth defects
Fig. 1 Main results from the observational studies [13–16] that detected an association between the use of antihyroid drugs in early pregnancy
and birth defects. The figure illustrates the prevalence of birth defects in non-exposed children and in children exposed to maternal treatment
with Propylthiouracil (PTU) or Methimazole (MMI) in early pregnancy. *indicates statistical significant difference for comparison to the
non-exposed group
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was substantiated (Fig. 1). Thus, MMI was associated
with a higher risk of birth defects in a number of organ
systems and with the severe malformations previously
described. A higher frequency of birth defects after ex-
posure to PTU was also observed (Fig. 1), but the associ-
ation was at the border of statistical significance.
Notably, an association with the subtypes of birth defects
previously associated with PTU was still observed in the
extended Danish cohort and supports an association
[16].
When considering the findings and the disparity in re-
sults from different studies, details of outcome assess-
ment may be of importance. Birth defects, also known as
congenital malformations, are by definition present at
birth [22]. However, this does not imply that all defects
are diagnosed at birth. Firstly, none of the observational
studies illustrated in Figs. 1 and 2 included data on pre-
natally diagnosed malformations from the use of ultra-
sound in pregnancy. The lack of such information may
bias the associations observed particularly for the more
severe malformations that could lead to the termination
of a pregnancy. Secondly, some birth defects may not
manifest until later in life and whether and when a mal-
formation is diagnosed will depend on when the child is
examined and what the examiner is looking for. Thus, it
should be expected that particularly less severe malfor-
mations are diagnosed with a delay. In general, the
prevalence of birth defects is 3% at birth increasing to
6% at two years of age [22]. Notably, the reported preva-
lence of birth defects among non-exposed children
ranged from 0.7 to 8.0% in the observational studies in-
vestigating the association between maternal use of
ATDs in early pregnancy and birth defects (Figs. 1 and
2). This may be partly due to the different follow-up
time for diagnosis of birth defects (ranging up to the age
of two years), but may also reflect other disparities (ma-
ternal report or examination by medical doctor, in- and/
or outpatient diagnoses, types of malformations) [12].
The studies from Denmark [15, 16] and Korea [14] were
register-based studies, and the children were followed to
the age of two and one year of age, respectively, for any
diagnoses of birth defects. In these studies [14–16], the
type of malformations associated with exposure to PTU
differed from those observed after MMI, and a detailed
examination of these birth defects in the Danish study
showed that they were confined to the face and neck re-
gion and the urinary system, and they appeared less se-
vere [23]. On the other hand, the birth defects observed
after exposure to PTU in the study from Korea [14] were
confined to the urinary system and the musculoskeletal
system, whereas no association with malformations of
the face and neck region was observed. The study by
Korelitz et al. from the US published in 2013 included
915 PTU-exposed children (Fig. 2). No overall associ-
ation with PTU was observed in this study, but consider-
ing subtypes of birth defects results indicated a higher
risk of malformation of the urinary system after expos-
ure to PTU. The Danish [15, 16] and the Korean [14]
studies both used the 10th revision of the International
Classification of Disease (ICD) to identify birth defects
in the child, whereas the US study [20] used the 9th re-
vision of the ICD. As specified above, the age at follow-
up differed between the studies. Furthermore, malforma-
tion of the face and neck region were classified together
with those of the eye and the ear in the Korean study
[14], whereas these malformation were evaluated in sep-
arate groups in the Danish studies [15, 16] and not spe-
cifically evaluated in the US study [20]. Adding to these
considerations, the subtypes of malformations are rare,
and it may be speculated if disparities in registration
practice exist. Overall, the findings from different popu-
lations emphasize that further studies with more cases
are needed to settle the teratogenic role of PTU, and the
low prevalence of subtypes of birth defects call for large
studies and extended follow-up.
On the biological gradient
Strength, consistency and specificity are some of the key
determinants of causality in observational studies [24].
Another determinant is the presence of a biological
Fig. 2 Main results from the observational studies [17–21] that found no association between the use of antihyroid drugs in early pregnancy and
birth defects. The figure illustrates the prevalence of birth defects in non-exposed children and in children exposed to maternal treatment with
Propylthiouracil (PTU) or Methimazole (MMI) in early pregnancy
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gradient in the associations observed [24]. As mentioned
above, one of the methodological challenges when study-
ing the association between in utero exposure and birth
defects is the low prevalence of subtypes of malforma-
tions. This necessitates large study populations to obtain
a sufficient number of exposed cases. Nationwide health
registers available in different countries constitute a
unique data source suitable for this purpose while provid-
ing a large study population and a low risk of selection
bias. On the other hand, such registers are secondary re-
search data meaning they are typically not collected with
the primary intention of doing research [25]. This proced-
ure may limit the available information of exposure and
outcome. More detailed information is often available in
studies that rely on the review of medical records, but this
methodology often applies to a smaller study population,
and the inclusion of patients from a specialized hospital
department may inherit a risk of selection bias [26, 27].
Another methodological aspect is that the type of non-
exposed control group differs between studies. Some stud-
ies included women with Graves’ disease who did not
receive ATD in the pregnancy, while others attempted to
include ‘thyroid healthy’ controls. This diversity in the
choice of comparison group may influence study results
and conclusions and challenge the assessment of the role
ATD as opposed to other exposures related to maternal
thyroid disease and thyroid autoimmunity.
Considering information on the dose of ATDs used
for the treatment of hyperthyroidism in early pregnancy,
this information was reported in a subset of observational
studies (Table 1). The two studies form Japan [10, 13] relied
on the review of medical records and found no evidence of
a dose-dependent association. The study by Momotani
et al. [10] (Table 1) included 643 children born to mothers
with GD in the period from 1965 to 1980. A total of 243
children had been exposed to maternal use of MMI in the
pregnancy and two of these children had a birth defect.
Details on the maternal MMI treatment revealed that these
children were born to mothers treated with a daily dose of
5 and 20mg MMI, respectively, and a cumulative dose of
160 and 240mg. The mean dose of maternal MMI treat-
ment among the 241 exposed non-cases (children with no
birth defect) was not reported, but it was concluded from
these limited data that there was no dose-dependency of
MMI on the occurrence of malformations [10]. In the more
recent and larger study from Japan published in 2012 by
Yoshihara et al. [13] (Table 1), it was reported that the
mean dose of MMI among all exposed pregnancies was 5
mg/day (standard deviation: 8.1mg/day) and that the dose
of MMI did not differ between cases of birth defects (n =
50) and controls (n = 1181), p = 0.13. Notably, it appeared
from the description of individual cases that the mean daily
dose of MMI was 9mg in cases of aplasia cutis (n = 8), 17
mg in omphalocele (n = 8), and 13mg in cases of omphalo-
mesenteric duct anomalies (n = 8), but no measure of com-
parison to exposed non-cases was reported [13]. The study
from Korea [14] (Table 1) was a large, nationwide study
and used data from the Korean National Health Insurance
database, which included a measure of the cumulative dose
of MMI and PTU during the first trimester of pregnancy. A
dose-dependent relationship was reported for MMI in
which case the prevalence of birth defects was higher with
a cumulative dose of > 495mg (n = 36 of 278; 13.0%) as
compared to 1–126mg (n = 21 of 282; 7.5%); adjusted odds
ratio 1.87 (95% confidence interval (CI): 1.06–3.30). This
was not the case for PTU with a similar prevalence of birth
defects among children exposed to a cumulative dose of >
8600mg (n = 159 of 2466; 6.5%) as compared to 1–1850
mg (n = 184 of 2502; 7.4%); adjusted odds ratio 0.90 (95%
CI: 0.72–1.12) [14]. No information on the mean daily dose
of MMI and PTU was reported, but when the cumulative
doses reported are considered relatively to the duration of a
first trimester, the dose-dependent relationship appears to
be present even when relatively small doses of MMI are
compared. This is the first study [14] to suggest a biological
gradient in the associations observed, and it is a notable
finding that dose-dependency was observed for MMI, but
not for PTU. However, there are difficulties related to the
assessment of a dose-dependent effect since the individual
dose of ATD may vary by week of pregnancy and the indir-
ect measure of exposure from redeemed prescriptions of
drugs bring about some uncertainty on the exact timing
and dose of exposure. Further studies are warranted to ex-
tend the findings including studies with detailed informa-
tion on the daily dose, exact timing of exposure and a
wider range of doses.
Table 1 Observational studies on the association between the dose of Methimazole used in early pregnancy and outcome of birth
defects
Author Year Country Data source Exposed (n)a Dose definition Associationb
Momotani et al. [10] 1984 Japan Medical records 243 Cumulative dose (range: 10–1680 mg)
Daily dose (categories: 5, 10, 15, 20, and≥ 30 mg)
No
Yoshihara et al. [13] 2012 Japan Medical records 1231 Daily dose (mean: 5 mg/day, standard deviation: 8.1 mg) No
Seo et al. [14] 2018 Korea Nationwide registers 1120 Cumulative dose (categories: 1–126, 127–260, 261–495,
and > 495mg)
Yes
aNumber of children exposed to maternal use of Methimazole in the early pregnancy
bIndicates whether a dose-dependent association between Methimazole and birth defects was observed, see text for details
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On thyroid function per se
Another key aspect to consider in terms of causality
from observational findings is analogy [24]. Namely, to
address the likelihood of other possible explanations in
the associations observed. For the association between
ATDs and birth defects, the role of maternal thyroid
function should be considered. As with details on treat-
ment dose, information on maternal thyroid function in
pregnancy is not always obtainable, especially when sec-
ondary data sources are used [25]. Data on maternal thy-
roid function in pregnancy were available and reported
in a subset of the observational studies on the use of
ATDs and birth defects (Table 2). The study by Momo-
tani et al. [10] published in 1984 concluded that mater-
nal hyperthyroidism per se was the main determinant of
birth defects in the offspring, whereas a smaller study
from Italy [19] and the larger studies from Japan [13]
and Denmark [15] found no evidence of an association
between maternal thyroid function and birth defects.
Notably, the methods used for assessment of maternal
thyroid function in pregnancy differed between the stud-
ies including the type of assay and the reference ranges
used for classification for maternal thyroid function
(Table 2). Furthermore, the subtype of maternal thyroid
dysfunction, the timing of exposure in relation to the
early pregnancy period and the choice of non-exposed
control group differed and limits the possibility to draw
definite conclusions.
The study by Momotani et al. [10] (Table 2) included
pregnant women with GD from a hospital clinic and in
the majority of cases, a free T4 index was used for as-
sessment of maternal thyroid function. No further de-
tails on the assay, the reference ranges used, and the
timing of sampling in pregnancy were reported, but it
was stated that the influence of pregnancy on the normal
range of thyroid function tests was considered. In this
study [10], the frequency of birth defects was higher in
hyperthyroid women (n = 5 of 167; 3.0%) than in euthyr-
oid women (n = 1 of 476; 0.2%), p < 0.01, however, the
number of exposed cases was small, and the low preva-
lence of birth defects in non-exposed children is not in
accordance with findings in later thorough studies. In
the later and larger Japanese study by Yoshihara et al.
[13] (Table 2), the assessment of maternal thyroid func-
tion in patients with GD was made from free T4 in the
first trimester (after the first trimester for a subgroup of
the patients) using two different automatic immunoassays,
and results were evaluated according to a uniform
trimester-specific reference range. In this study [13], the
impact of maternal thyroid function was assessed in the
non-exposed group, in the MMI-exposed group, and in
the PTU-exposed group, respectively. No difference in the
frequency of birth defects was observed when stratified by
maternal hyperthyroidism within these groups, and in an
adjusted model, maternal thyroid function did not associ-
ate with birth defects (adjusted odds ratio: 0.86 (95% CI:
0.63–1.1) [13]. In the study from Italy [19], 176 pregnant
women with GD were treated with ATDs in pregnancy
and had thyroid function assessed monthly. A total of 55
women were classified as hyperthyroid, because biochem-
ical hyperthyroidism was seen twice during the pregnancy.
For comparison, 121 euthyroid women treated with ATD
were included as were 203 euthyroid pregnant women di-
agnosed with other subtypes of thyroid disease. No meas-
ure of comparison was provided, but it was concluded
that the rate of malformations was not higher in any of
the groups investigated than in the general population.
The most recent study from Denmark [16] differed
from the Japanese studies [10, 13] and from the Italian
study [19] in terms of the study population and the as-
sessment of maternal thyroid function (Table 2). This
study [16] included the measurement of TSH and free
T4 in two independent cohorts using stored blood sam-
ples from 7624 pregnant women enrolled in the Danish
National Birth Cohort (DNBC) and from 14,483 preg-
nant women enrolled in the North Denmark Region
Pregnancy Cohort (NDRPC). Thus, these study popula-
tions were not confined to women with GD from a
Table 2 Observational studies on maternal thyroid function in early pregnancy and outcome of birth defects
Author Year Country Sample Exposed (n)a Thyroid function tests Assays Reference range Associationb
Momotani et al. [10] 1984 Japan Clinical 167 Free T4 indexc Not specified Not specified Yes
Yoshihara et al. [13] 2012 Japan Clinical Not specified Free T4 Lumipulse, Fuji Rebio or
ECLusys, Roche Diagnostics
Trimester No
Gianetti et al. [19] 2015 Italy Clinical 55 Free T4, free T3
and TSH
FT4 kit and FT3 kit,
Technogenetics
Delfia hTSH, Pharmacia
Not specified No
Andersen et al. [16] 2019 Denmark Biobank 951 Free T4 and TSH Dimension Vista, Siemens
Healthineers
Pregnancy week No
Andersen et al. [16] 2019 Denmark Biobank 2183 Free T4 and TSH Advia Centaur XP, Siemens
Healthineers
Pregnancy week No
aNumber of children exposed to abnormal maternal thyroid function in the early pregnancy
bIndicates whether an association between abnormal maternal thyroid function and birth defects was observed, see text for details
cIn some cases the total T4, T3 and/or PBI concentration was measured
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hospital department. Furthermore, pregnancy-week spe-
cific reference ranges established within each cohort
were used for assessment of maternal thyroid function
in the early pregnancy (median week 9–10). Overall, no
association between maternal thyroid function and birth
defects was observed in these cohorts (DNBC: adjusted
hazard ratio 1.02 (95% CI: 0.86–1.22), NDRPC: 1.03
(0.82–1.30)). For subtypes of maternal thyroid dysfunc-
tion, no association between hyperthyroidism and birth
defects was observed. However, in one of the cohorts,
maternal overt hypothyroidism was a risk factor for birth
defects in the child (adjusted hazard ratio: 1.91 (95% CI:
1.12–3.25), and this associated was dominated by mal-
formations of the heart [16]. In the Japanese study from
2012 [13], it was also reported that the frequency of
birth defects was higher in hypothyroid women com-
pared to euthyroid women, and other observational
studies investigating maternal thyroid function in preg-
nancy, but not exposure to ATDs, have indicated that
maternal hypothyroidism may be a risk factor for birth
defects including congenital heart defects [28–31]. How-
ever, studies are heterogeneous in the definition of ex-
posure and outcome, and the underlying mechanisms
are not clear. Thus, further studies are needed to address
the association between maternal thyroid function in
early pregnancy and birth defects including the differen-
tial exposure to ATDs and/or abnormal thyroid function
and the potential risk of side effects related to over- and
under-treatment of maternal thyroid disease.
Timing and type of treatment
Results of the large observational studies published dur-
ing the last decade have substantiated a concern about
teratogenic side effects to the use of all ATDs in early
pregnancy. Such findings challenge the clinical practice
and have led to a re-evaluation of the clinical recom-
mendations [2–4]. In the current guidelines [2–4], PTU
is recommended for the treatment of hyperthyroidism in
pregnancy with a focus on early pregnancy detection
and early shift from MMI to PTU. Furthermore, the
findings that all clinically available ATDs may be associ-
ated with birth defects have led to considerations on the
timing and type of treatment [8]. This includes the bene-
fits and risks of definitive treatment prior to pregnancy
or a withdrawing of ATDs during the early pregnancy
weeks in appropriately selected patients as well as con-
siderations on alternative treatment options.
Considering the timing of exposure, a subset of the
observational studies performed included a group of
children considered as exposed to both MMI and PTU
in early pregnancy (Table 3). Half of the studies reported
that such ‘double exposure’ was associated with a higher
risk of birth defects as compared to non-exposed (Table
3). The number of exposed children was limited in the
majority of studies (Table 3), but the identification of
these pregnancies is of clinical importance considering
the timing of a shift from MMI to PTU in relation to
pregnancy start. Notably, all studies were register-based
and relied on an indirect measure of exposure which
challenges the exact assessment of the type and timing
of exposure around the pregnancy start. Thus, not only
information on double exposure, but also the type of ex-
posure in the period before and after pregnancy start is
important to evaluate [32]. A more detailed evaluation
of double exposed cases has indicated that the duration
of MMI exposure in early pregnancy is critical [8]. This
finding may favor a shift in therapy prior to pregnancy
also given that the critical window of exposure is from
pregnancy week 6 to 10 [8]. Thus, it may be difficult to
arrange a shift in therapy after pregnancy detection and
prior to this critical period.
In addition to the choice of treatment in early preg-
nancy, a pertinent question is on the choice of treatment
after the embryonic period of early pregnancy. A general
concern about the use of PTU in non-pregnant individ-
uals has been the risk of fulminant liver failure. Such
concern has favored the use of MMI, particularly in chil-
dren [33]. Only few observational studies addressed the
risk of liver failure associated with the use of ATDs in
pregnant women specifically [21, 34, 35]. Overall, this
severe side effect was rarely seen in pregnant women,
and in the Danish study [35], birth defects was the pre-
dominant side effect to the use of ATD in pregnancy as
compared to both liver failure and agranulocytosis. At
present, the preferred choice of treatment after the first
trimester of pregnancy remains uncertain [2–4]. The im-
munological changes during a pregnancy characterized
by immunosuppression may attenuate the hyperthyroid-
ism of GD and the indication for treatment and the dose
of treatment should be carefully monitored with swift
adjustments to meet the change in need. Along with
considerations on the type and severity of side effects, a
shift in therapy may introduce a risk of less controlled
hyperthyroidism. Clearly, more evidence is needed, and
studies with detailed assessment of the type and timing
of exposure are warranted to inform the clinical guid-
ance on the when and how to treat maternal hyperthy-
roidism throughout the pregnancy [32].
Considering alternative treatments, a focus on the
feasibility of using potassium iodide has emerged from
studies in Japan [36, 37]. In a cohort of 283 pregnant
women with GD, treatment had been switched from
MMI to potassium iodide in early pregnancy due to in-
tolerance to PTU [36]. These cases were retrospectively
reviewed, and the prevalence of birth defects was evalu-
ated according to treatment. In this study [36], the
prevalence of birth defects was lower in the group
treated with potassium iodide (n = 4 of 260; 1.5%) as
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compared to the group treated with MMI (n = 47 of
1134; 4.1%), p < 0.05, including a lower prevalence of the
severe malformations previously described as part of the
MMI embryopathy. There was no difference between
the two groups in terms of gestational age at birth, birth
weight or perinatal losses, but the frequency of early
pregnancy loss was higher in the MMI group (n = 164 of
1333; 12.3%) as compared to the iodine groups (n = 15
of 283; 5.3%), p < 0.05. The authors speculated whether
this finding was related to maternal thyroid function in
early pregnancy [36]. A general concern about the use of
iodine for the treatment of hyperthyroidism is that this
treatment may be less effective than ATDs in the control
of hyperthyroidism [6]. In a subsequent study from
Japan [37], focus was on thyroid function in pregnant
women who shifted from MMI to potassium iodide. In a
cohort of 240 pregnant women, nearly half of the pa-
tients continued treatment throughout pregnancy and
around 10% could not have their hyperthyroidism con-
trolled solely by potassium iodide [37]. From a clinical
point, the identification of these patients is important
considering the choice of treatment, but no specific pre-
dictors of this tendency to escape from the antithyroid
effect of iodine could be identified in that study [37].
Further studies on the benefits and risks of treatment
with potassium iodide in early pregnancy are needed in-
cluding studies from populations with different levels of
iodine intake.
Another pertinent question is the possibility of other
treatments or the development of new treatment. This
perspective of alternative treatments on the one hand
and the proposal of treatment withdrawal in early preg-
nancy on the other hand call for further research. Clin-
ical studies are needed and basic scientific work is
important to support the clinical data and to develop
our understanding of the mechanisms by which ATDs
cause teratogenic side effects. Furthermore, different
types of research serve to determine the role of maternal
thyroid function and the role of the autoimmune mecha-
nisms associated with the hyperthyroidism of GD. MMI
and PTU are considered to equally cross the placenta
[38], to be equally effective in the control of hyperthy-
roidism in pregnancy [39] and to hold the same risk of
inducing fetal hypothyroidism [40]. However, more evi-
dence is needed to unveil the mechanisms underlying
their teratogenic potential. Many possible mechanisms
are in play, and one may also speculate on the possible
interaction between ATD, maternal and fetal thyroid
function, and thyroid autoimmunity and how these vari-
ous exposures may have direct or indirect adverse
effects.
Conclusion
A link between the use of ATDs for the treatment of
hyperthyroidism in early pregnancy and birth defects has
been brought forward over the past 50 years, and large
observational studies have quantified the risk of birth de-
fects associated with different types of ATDs in more re-
cent years. Current evidence substantiates a risk of birth
defects associated with the use of MMI and these mal-
formations may be severe. On the other hand, further
studies are needed to settle the teratogenic role of PTU
and the role of maternal thyroid function and thyroid
autoimmunity. Detailed clinical data on the timing and
type of exposure in early pregnancy are needed to in-
form clinical practice on the choice of treatment and the
possibility of treatment withdrawal in selected patients.
Furthermore, basic scientific work is important to ad-
dress the mechanisms underlying the development of
birth defects, and to precede the development of alterna-
tive or new treatments with less severe side effects.
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